Human CD20 Protein-VLP (LTP10401)
$ 1576 In stock B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
Recombinant Human CD20 Protein-VLP is expressed from Expi293. It contains Met1-Pro297.
The target protein has a predicted MW of 34.3 kDa.
Immobilized Human CD20 VLP at 5ug/ml (100ul/Well) on plate on the plate. Dose response curve for Rituximab, hFc Tag with the EC50 of 8.7ng/ml determined by ELISA (QC Test). See testing image for detail.
> 95% as determined by HPLC
Less than 1EU per ug by the LAL method.
Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. Notice: If you need it for immunization, Do Not use any adjuvant.
Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Shipped at ambient temperature.
Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.